Positioning NK-κB in multiple myeloma

Slides:

Advertisements

Similar presentations

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Advertisements

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Gene therapy: efficient targeting of hematopoietic stem cells

Uncontrolled Wnt signaling causes leukemia

Collaboration is required for successful immunotherapy

“Vitamin hypothesis”: explanation for allergy increase?

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

A Nurr1 Pathway for Neuroprotection

Another Notch on the belt

Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-κB and c-Jun N-terminal kinase by Ingrid Pollet, Christy.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Juvenile Myelomonocytic Leukemia

BTK inhibition in myeloma: targeting the seed and the soil

BRAF inhibitor: targeted therapy in hairy cell leukemia

A cell by any other name by Narla Mohandas Blood

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Transplants for the elderly in myeloma

Mechanical Properties of Stored Red Blood Cells Using Optical Tweezers

V617F “JAKs” up myeloproliferative signal

RNA interference in biology and disease

Fusion genes in cord blood

Immunologic pathomechanism of Hodgkin's lymphoma

Targeting kinases in CML CLL

Telomerase regulation in HTLV-I infection

Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment Tao Xu, Hongxiang Wang, Xiaoquan Huang, Weiqing Li, Qilin.

Deep mining of the RBC proteome

by Keren Mizrahi, and Nadir Askenasy

Figure 1 A schematic representation of the HER2 signalling pathway

Target recognition–induced NK-cell responses

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Walter Zumkeller, and Stefan Burdach

Ph+ ALL: drawing strength from a benign past

Targeted Therapies in Melanoma: Translational Research at Its Finest

Qingfei Jiang, Catriona Jamieson Cancer Cell

To the heart of the APS puzzle

Janus Kinase Deregulation in Leukemia and Lymphoma

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome

Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide Weishan Huang, PhD, J. Luis Morales,

by Alex Aleshin, and Peter L. Greenberg

Experimental Hematology

Killing Lymphoma with Smac-Mimetics: As Easy as ABC?

Control of B Lymphocyte Apoptosis by the Transcription Factor NF-κB

Unraveling the Warp and Weft of B Cell Fate

Dolors Colomer, Elías Campo Cancer Cell

Raquel Espín-Palazón, David Traver Experimental Hematology

NF-κB activation in pathogenesis and therapy of cancer.

Oncogenic ALK signaling.

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Tumor necrosis factor α in the onset and progression of leukemia

Kinase signaling and targeted therapy for primary myelofibrosis

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

HoxA9 directly regulates cell cycle control genes.

The new kid on the block(ade) of the IGF-1 receptor

Overcoming “aspirin resistance” in MPN

Matthew I. Stein, Jiang Zhu, Stephen G. Emerson

Anti-CD20-IL-21 fusokine: the tail wags the dog

by Abigail M. Druck Shudofsky, and Chou-Zen Giam

Attacking Cancer at Its Root

NOTCH1 and MYC regulate leukemia cell growth.

Apoptosis: Activate NF-κB or die?

Pure red cell aplasia by Robert T. Means Blood

Characterization of the MM.1 human multiple myeloma (MM) cell lines

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

Positioning NK-κB in multiple myeloma by Bernard Klein Blood Volume 115(17):3422-3424 April 29, 2010 ©2010 by American Society of Hematology

The main gene abnormalities targeting NF-κB pathway are displayed in red and italic font. The main gene abnormalities targeting NF-κB pathway are displayed in red and italic font. They result in aberrant activation of noncanonical and canonical NF-κB pathway that together with other signaling pathway activation (JAK/STAT, MAP kinase, PI3K/AKT) trigger myeloma cell survival, proliferation and drug resistance. Bernard Klein Blood 2010;115:3422-3424 ©2010 by American Society of Hematology